Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Coronary Microvascular Dysfunction, Heart Failure With Preserved Ejection Fraction (HFpEF)
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
The purpose of this study is to examine small vessel disease (a condition in which the small arteries in the heart become narrowed).
- Trial name
- NCT03876223
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure, Congestive Heart Failure
Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint).
- Trial name
- NCT01516346
- Testing
- Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Heart Failure
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant…
- Trial name
- HFpEF (NCT02876042)
- Testing
- BAROSTIM NEO™ System
- Where
- 13 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CVRx, Inc.
Heart Failure, Heart Failure, Systolic
Predicting Heart Failure Outcomes With Biomarkers and Imaging
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BIOPHF (NCT07332520)
- Volunteers
- 4,000 people
- Sponsor
- Xinjiang Medical University
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Extended IASD Investigation: REDUCE LAP-HF IV
Multicenter, Prospective, Open Label, Single Arm, Clinical Trial. The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients…
- Trial name
- NCT04632160
- Testing
- IASD System II
- Sponsor
- Corvia Medical
Heart Failure With Preserved Ejection Fraction (HFPEF)
Effects of a Multicomponent Training Program on Cardiac Function, Skeletal Muscle Metabolism, Functional Capacity, and Quality of Life in Patients With HFpEF: SENSORFIT-4HEART Study
Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome with increasing incidence and poor prognosis, accounting for up to 50% of heart failure cases.
- Trial name
- SENSORFIT-4HEA (NCT07251361)
- Testing
- Supervised training
- Where
- Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universidad Pública de Navarra
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Tailored Exercise Training Study Among Adults With HFpEF
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF.
- Trial name
- TEXPEF (NCT07223242)
- Testing
- Moderate-intensity continuous training (MCT), Resistance training, Weight loss
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure With Preserved Ejection Fraction
Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction
The goal of this observational study is to evaluating myocardial stiffness in patients with heart failure with preserved ejection fraction (HFpEF) by intrinsic wave velocity propagation (IVP).
- Trial name
- NCT06196086
- Testing
- Echocardiography examination
- Where
- China
- Volunteers
- 438 people, healthy volunteers welcome
- Sponsor
- Haiyan Wang
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Cardiac TTR Amyloidosis
Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease
Cardiac amyloidosis is a multi-organ syndrome, which usually presents as restrictive cardiomyopathy (RCM). Transthyretin (TTR) amyloidosis (or ATTR) is a subtype of amyloidosis which frequently involves heart.
- Trial name
- NCT03098901
- Testing
- Tc99m-labeled pyrophosphate scan
- Volunteers
- 100 people
- Sponsor
- Kaplan Medical Center
Heart Failure, Heart Failure With Preserved Ejection Fraction
PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study
This is a prospective multicenter study to decipher phenotypic variability within patients with heart failure and preserved left ventricular ejection fraction (HFpEF).
- Trial name
- NCT04189029
- Testing
- Extensive phenotyping
- Where
- France
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure, Heart Failure With Preserved Ejection Fraction
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
- Trial name
- NCT05592275
- Testing
- LY3540378
- Where
- 137 sites in United States, Argentina and 10 more
- Volunteers
- 332 people
- Sponsor
- Eli Lilly and Company
Pulmonary Hypertension, Heart Failure
Metformin for Pulmonary Hypertension HFpEF
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
- Trial name
- PH-HFpEF (NCT03629340)
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Francisco
HFpEF, Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes
Using cardiac magnetic resonance imaging technology, the ejection fraction of heart failure (HFpEF) and different subtypes of cardiac magnetic resonance characteristics, and combined with the clinical characteristics and…
- Trial name
- NCT06916611
- Testing
- Cardiac Magnetic Resonance Imaging
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Heart Failure With Preserved Ejection Fraction (HFPEF)
Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction
Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours
- Trial name
- NCT07634640
- Testing
- Ferumoxytol infusion
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Florida
Heart Failure
A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects
AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator. AZD9977 is a partial antagonist and partial agonist in reporter gene assays and has a different interaction pattern with the MR compared to eplerenone.
- Trial name
- NCT03804645
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure, Preserved Ejection Fraction
Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction
Retrospective review of 492 patient from a small community hospital who did not qualify for participation in the Connect HF study sponsored by DCRI.
- Trial name
- NCT04008914
- Testing
- retrospective observation
- Where
- United States
- Volunteers
- 492 people
- Sponsor
- Ascension Macomb-Oakland Hospital
HFpEF
Muscle Blood Flow Regulation in HFpEF
Heart failure with preserved ejection (HFpEF) disproportionately affects Veterans and is the number one reason for hospital discharge in the VA Health Care System.
- Trial name
- NCT05115890
- Testing
- Exercise training
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
Resmetirom in Patients With MASH and HFpEF
This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis…
- Trial name
- NCT07830758
- Testing
- Resmetirom
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Pulmonary Hypertension
Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
This study will assess the impact of sacubitril/valsartan on elevated pulmonary artery (PA) pressures in patients with heart failure (HF) with preserved ejection fraction (HFpEF), measured using a previously implanted hemodynamic…
- Trial name
- ARNIMEMS-HFpEF (NCT04753112)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Germans Trias i Pujol Hospital